MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
申请人:Vertex Pharmaceuticals Incorporated
公开号:EP3798214A1
公开(公告)日:2021-03-31
The present invention features a compound of formula I:
or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.
本发明的特征是一种式 I 的化合物:
或其药学上可接受的盐,其中 R1、R2、R3、W、X、Y、Z、n、o、p 和 q 在本文中定义,用于治疗 CFTR 介导的疾病,如囊性纤维化。本发明还包括药物组合物、治疗方法及其试剂盒。
A hemilabile NHC‐gold complex and its application to the redox neutral 1,2‐oxyarylation of feedstock alkenes
作者:Samuel C. Scott、Jamie A. Cadge、Grace Boden、John Bower、Christopher A. Russell
DOI:10.1002/anie.202301526
日期:——
A hemi-labile (C^N) N-heterocyclic carbene ligand mediates oxidative addition of aryl iodides to a AuI center. The oxidative addition process has been studied and analyzed computationally. This process allows the first examples of “exogenous oxidant-free” AuI/AuIII catalyzed 1,2-oxyarylations of ethylene and propylene.
半不稳定 (C^N) N-杂环卡宾配体介导芳基碘化物与 Au I中心的氧化加成。对氧化加成过程进行了研究和计算分析。该过程实现了“无外源氧化剂”Au I /Au III催化乙烯和丙烯 1,2-氧基芳基化的第一个例子。